15,000 Shares in Upstream Bio, Inc. $UPB Purchased by ADAR1 Capital Management LLC

Key Points

• ADAR1 Capital Management LLC invested $92,000 in Upstream Bio, acquiring 15,000 shares during the first quarter.
• Multiple large investors, including Bank of America and Northern Trust Corp, have recently taken new stakes in Upstream Bio, reflecting growing interest in the company.
• Upstream Bio reported a quarterly loss of ($0.74) EPS, which was below analysts' expectations, with a negative net margin of 3,836.58% for the period.

ADAR1 Capital Management LLC acquired a new position in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 15,000 shares of the company's stock, valued at approximately $92,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Velan Capital Investment Management LP purchased a new stake in shares of Upstream Bio in the 1st quarter worth $655,000. Nuveen LLC purchased a new stake in shares of Upstream Bio in the 1st quarter worth $138,000. XTX Topco Ltd purchased a new stake in shares of Upstream Bio in the 1st quarter worth $78,000. New York State Common Retirement Fund purchased a new stake in shares of Upstream Bio in the 1st quarter worth $29,000. Finally, Wellington Management Group LLP purchased a new stake in shares of Upstream Bio in the 4th quarter worth $25,632,000.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised Upstream Bio from a "sell" rating to a "hold" rating in a report on Friday, June 6th. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $56.50.

Upstream Bio Trading Down 4.6%

Shares of Upstream Bio stock traded down $0.93 during trading on Monday, reaching $19.05. 164,673 shares of the stock traded hands, compared to its average volume of 370,150. The business has a fifty day simple moving average of $14.80 and a two-hundred day simple moving average of $10.92. Upstream Bio, Inc. has a 52-week low of $5.14 and a 52-week high of $29.46.

Upstream Bio (NASDAQ:UPB - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.13). The firm had revenue of $0.94 million for the quarter, compared to analysts' expectations of $0.32 million. Upstream Bio had a negative net margin of 3,836.58% and a negative return on equity of 35.90%. Equities research analysts anticipate that Upstream Bio, Inc. will post -4.3 EPS for the current fiscal year.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.